XOMA Royalty amends merger agreement to add newly formed holding company for Ligand acquisition

XOMA Royalty Corp

HoldCo (XOMA Royalty Holdings Corporation) formed on May 15, 2026 and added as party to the Merger Agreement with Ligand Pharmaceuticals.
Amendment No. 1, dated May 16, 2026, among XOMA Royalty, HoldCo, Ligand, and Merger Sub, facilitates the holding company reorganization.
HoldCo will survive the merger as a wholly owned subsidiary of Ligand; references in the Merger Agreement are updated accordingly.
Changes include replacing 'Company' with 'Surviving Corporation' in Sections 1.5 and 5.23, and updating the NRS statutory reference.
Overall terms of the Merger Agreement remain unchanged; the amendment is procedural for the previously announced acquisition.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.